Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Elite Pharma Inc (ELTP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 96,091
  • Shares Outstanding, K 775,550
  • Annual Sales, $ 9,640 K
  • Annual Income, $ 3,810 K
  • 36-Month Beta -0.10
  • Price/Sales 9.98
  • Price/Cash Flow 0.00
  • Price/Book 4.44
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.01
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 08/08/17
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0960 +21.56%
on 07/07/17
0.1999 -41.62%
on 06/22/17
-0.0833 (-41.65%)
since 06/20/17
3-Month
0.0960 +21.56%
on 07/07/17
0.2495 -53.23%
on 05/15/17
-0.0307 (-20.83%)
since 04/20/17
52-Week
0.0960 +21.56%
on 07/07/17
0.2495 -53.23%
on 05/15/17
-0.0783 (-40.15%)
since 07/20/16

Most Recent Stories

More News
Elite Announces New Development and License Agreement with SunGen Pharma LLC

Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced it has entered into...

ELTP : 0.1167 (-5.81%)
Elite Pharmaceuticals Reports Positive Topline Results from a Pivotal Bioequivalence Study

Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today reported positive topline results from pivotal bioequivalence studies conducted in April of this year for an undisclosed generic...

ELTP : 0.1167 (-5.81%)
Elite Pharmaceuticals' SequestOx(TM) Study Results Expected in July

Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP), today announced that top-line results for its reformulated SequestOx(TM) study are expected in July 2017. Patient disqualification and...

ELTP : 0.1167 (-5.81%)
Elite Pharmaceuticals Acquires Trimipramine ANDA

Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP), today announced the acquisition of an approved and currently marketed Abbreviated New Drug Application ("ANDA") for Trimipramine Maleate...

ELTP : 0.1167 (-5.81%)
RDY : 42.06 (-1.06%)
Elite Pharmaceuticals Files ANDA for Pain Product

Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced that it had filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (FDA) for a generic...

ELTP : 0.1167 (-5.81%)
Elite Pharmaceuticals, Inc. Reports Results for Third Quarter of Fiscal Year 2017

Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP), announced results for the quarter ended December 31, 2016, the third quarter of its 2017 fiscal year.

ELTP : 0.1167 (-5.81%)
Elite Pharmaceuticals Reports Positive Topline Results from a Pivotal Bioequivalence Study for a Generic OxyContin(R)

Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today reported positive topline results from a pivotal bioequivalence fed study initiated in November 2016. The topline results indicate...

ELTP : 0.1167 (-5.81%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

See More

Support & Resistance

2nd Resistance Point 0.1306
1st Resistance Point 0.1273
Last Price 0.1167
1st Support Level 0.1178
2nd Support Level 0.1116

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.